

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

J.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

IPE	no persons are required to respond to a col Application Number	10/750,996	unicss		
O' TEANGMITTAL	Filing Date	+	2002		
P 1	First Named Inventor	December 31			
NOV 2 5 2005 FORM	Art Unit	Antoni Kozlo			
<i>16</i> −1	Examiner Name	1626	1626		
(to be used to all correspondence after initial in the state of the st	filing)	Unknown			
Total Number of Pages in This Submission	Attorney Docket Number	SHE0065.00			
	ENCLOSURES (Check all	that apply)	-		
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence A Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD Remarks	Address X 7 City Posto	Appea of App Appea (Appe Propri Status Other below	Allowance Communication to TC al Communication to Board beals and Interferences al Communication to TC al Notice, Brief, Reply Brief) fetary Information s Letter Enclosure(s) (please Identify): Perences and Return Receipt	
CIONA	FURE OF ARRUPANT, ATTO	DUEW OR AG			
Firm Name	TURE OF APPLICANT, ATTO	KINEY, OR AG	ENI		
NEKTAR THERAI	PEUTICS				
Signature Mul a. Wil	lsen				
Printed name Mark A. Wilson					
Date November 22, 2	005 F	Reg. No. 43,27	75		
CE	ERTIFICATE OF TRANSMISSI	ON/MAILING			
I hereby certify that this correspondence is be sufficient postage as first class mail in an env the date shown below:	eing facsimile transmitted to the USPTO elope addressed to: Commissioner for	O or deposited with Patents, P.O. Box	h the Un k 1450, /	ited States Postal Service with Alexandria, VA 22313-1450 on	
Signature M / // // // // // // // // // // // //	o Cotta				
Typed or printed name Minna Cotter			Date	11/22/2005	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

OFF TROPS		
NOV 2 5 2005 PY THE UNITED STATES PA	ATENT AND TRADEMARK OFFIC	E
Mertha and Scation of: Antoni Kozlowski et a	al.) Atty. Docket No.: SHE0065	5.00
) Examiner: Unknown	
Application No.: 10/750,996) Group Art Unit: 1626	
Filed: 12/31/2003)	
Title: MALEAMIC ACID POLYMER DERIVATIVES AND THEIR BIOCONJUGATES))))	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, Virginia 22313-1450 on November

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

The references listed in the attached Forms PTO/SB/08A and B may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

In compliance with 37 CFR §§1.98, enclosed are copies of each foreign patent and each publication or that portion which caused it to be listed, other than U.S. patents unless required by the Office.

This Is	nformati	ion Disclosure Statem	ent is be	eing timely filed under 37 CFR §§1.97 and is being filed:		
	\boxtimes	months of the date of	f entry o	ling date of a national application or an RCE; within three of the national stage as set forth in section 1.491 in an before the mailing date of a first Office action on the urs last);		
	Please	charge the amount of	<u>\$</u>	Deposit Account 500348		
\boxtimes	If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500348.					
				Respectfully submitted,		
				NEKTAR THERAPEUTICS		
Dated	Nove	164 22, 2005	Ву:	Mark A. Wilson Reg. No. 43,275		
	arlos, C 631-310	A 94070 00				

Form

Form PTO/SB/08A (Modified)

Information Disclosure Statement By Applicant

(Use Sev	eral Sheets	s if Necessary
----------	-------------	----------------

Atty. Docket No.:	Application No.:
SHE0065.00	10/750,996
Applicant:	
Antoni Ko	ozlowski et al.
Filing Date:	Group:

U.S. Patent Documents

Examiner						Sub-	Filing
Initial	No.	Patent No.	Date	Patentee	Class	Class	Date
	A	6,017,943	01/25/2000	Acharya et al.			
	В	6,875,841	04/05/2005				
	-		<u>-</u>				
		<u> </u>					
		-					
		L					

Examiner:	Date Considered:
23.44	Dute Considered.

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO/SB/08A (Modified)	Atty. Docket No.:	Application No.:	
	SHE0065.00	10/750,996	
Information Disclosure	Applicant:		
Statement By Applicant	Antoni Kozlowski et al.		
	Filing Date:	Group:	
(Use Several Sheets if Necessary)	12/31/2003	1626	

Foreign Patent or Published Foreign Patent Application

Examiner			Document	Publication	Country or		Sub-	Trans	lation
Initial		No.	No.	Date	Patent Office	Class	class	Yes	No
		С	0 273 545	07/06/1988	EP				
		D	0 839 849	05/06/1998	EP				
		Е	2000-191700	07/11/2000	JP				
		F	92/16221	10/01/1992	WO				
		G	99/03887	01/28/1999	WO				
			_						
					, and the second				
	\perp								
	\perp								
	\perp								
<u></u>	\perp								

Examiner:	Date Considered:
Diaminici.	Date Considered.

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO/SB/08B (Modified)	Atty. Docket No.:	Application No.:	
	SHE0065.00	10/750,996	
Information Disclosure	Applicant: Toni Kozlowski et al.		
Statement By Applicant			
	Filing Date:	Group:	
(Use Several Sheets if Necessary)	12/31/2003	1626	

Other Documents

Examiner			
Initial		No.	Author, Title, Date, Place (e.g. Journal) of Publication
		Н	TSUTSUMI ET AL., "Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38(LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity", PNAS, 97(15):8548-8553, (July 18, 2000)
		I	WU ET AL., "p53 protein oxidation in cultured cells in response to pyrrolidine dithiocarbamate: a novel method for relating the amount of p53 oxidation in vivo to the regulation of p53-responsive genes", Biochem. J., 351:87-93, (2000)
	\vdash		
	+		
	\dashv		
	+		
	T		
	\perp		
	+		
	\dashv		
	\top		

Examiner:	Date Considered:

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.